Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Anti-TNF, Vedolizumab and Tofacitinib on Vascular Stiffness and Cardiovascular Risk in Ulcerative Colitis
2024-517314-15-00Phase 4Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in autoimmune colitis (5 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Carotid intima media thickness (CIMT). Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-517314-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517314-15-00.